Chemed Corporation — 2015 Form 10-K
Reporting period: Fiscal year ended December 31, 2015. Although the request identifies 2015 Q4, this filing is an annual report; the supplied text does not provide clear standalone fourth-quarter financial results. Chemed operates through VITAS, a hospice and palliative-care provider, and Roto-Rooter, which provides plumbing, drain-cleaning and water-restoration services.
Financial performance and position
The filing incorporates the consolidated financial statements and management’s discussion from the 2015 Annual Report to Stockholders, but the supplied text does not include their detailed results. It therefore does not provide clear values here for annual revenue, profit, cash flow, margins, cash balances or segment results, or comparable-year changes in those measures.
- Debt and interest-rate exposure: Long-term debt was approximately $91.3 million at December 31, 2015, all at variable rates. The filing estimates that a 100-basis-point rate change changes annual interest expense by $100,000 for each $10 million borrowed under the credit facility.
- VITAS payer concentration: More than 90% of VITAS revenue came from Medicare and Medicaid; approximately 90% was from Medicare, according to the business discussion. Medicaid accounted for 5% of VITAS revenue in 2015. Government hospice payments are primarily per diem, making profitability sensitive to care costs and reimbursement rates.
- Shareholder returns: Quarterly dividends were $0.22 per share in the first and second quarters and $0.24 in the third and fourth quarters of 2015. The company repurchased 460,765 shares during the year, based on the quarterly totals shown, under its February 2011 program. The board authorized an additional $100 million for that program in March 2015.
- Environmental liability: The recorded accrual for potential DuBois-related cleanup costs was $1.7 million. Chemed also disclosed contingent exposure up to $14.9 million, for which no additional provision was recorded because management did not consider payment probable.
Changes, outlook and management commentary
- Medicare hospice reimbursement changed effective January 1, 2016: routine home care rates moved to a two-tier structure based on the first 60 days versus later care, and a service-intensity add-on began for qualifying nurse or social-worker visits near the end of a patient’s life. The filing does not quantify the expected net effect on Chemed.
- Chemed reported net costs related to the VITAS government action and related regulatory matters of $5.0 million in 2015, compared with $2.1 million in each of 2014 and 2013.
- Management stated that disclosure controls and procedures were effective at year-end and that no material change in internal control over financial reporting occurred during the fourth quarter. The filing refers readers to the incorporated annual report for the auditor’s internal-control report.
- Management did not provide a clear company-wide numerical forecast in the supplied filing text. It cautioned that future dividends depend on earnings, financial condition, debt-covenant compliance and other factors.
Key risks and contingencies
- VITAS False Claims Act case: The government alleges improper Medicare billing for continuous home care and patients allegedly ineligible for hospice. The complaint seeks treble damages and statutory penalties. Chemed said it could not reasonably estimate the probability or range of loss.
- Other litigation: Shareholder derivative cases related to alleged Medicare and Medicaid claims and internal controls were consolidated. A magistrate judge recommended dismissal, subject to district-court review; the lead plaintiff objected in January 2016. The company said it intended to defend the cases.
- Reimbursement and compliance: VITAS is highly exposed to government payment rates, caps, claims reviews, eligibility rules and extensive licensing and program requirements. Denials, recoupments, rate reductions or loss of program participation could materially affect results.
- Operations and workforce: VITAS faces nursing-staff shortages and wage pressure; Roto-Rooter faces fragmented competition and difficulty attracting skilled plumbers. Weather affects Roto-Rooter, while winter migration can increase VITAS admissions in Florida. A major hurricane could disrupt VITAS’s significant south Florida operations.
- Financing and other risks: Variable-rate debt creates interest expense exposure, and debt covenants may constrain operations. The filing also identifies cybersecurity, reputational, environmental and professional-liability risks.
Important facts for investors to verify
- Review the incorporated 2015 Annual Report for audited revenue, earnings, cash flow, margins, liquidity, segment performance and year-over-year comparisons; those detailed figures are not present in the supplied text.
- Check subsequent developments, estimated exposure and any reserves or settlements relating to the VITAS False Claims Act case and shareholder litigation.
- Assess Medicare and Medicaid reimbursement changes, hospice cap exposure, claims-audit outcomes and VITAS patient eligibility and care-cost trends.
- Verify debt balances, credit-facility availability, covenant headroom and sensitivity to variable interest rates.
- Confirm the status and expected cost of the DuBois environmental matters and whether any additional liability has become probable.